Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 40 NIH 11 NETWORK 10 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 16 Other hematologic neoplasm 13 Head & Neck 6 Breast 5 Myeloid 3 Thoracic 1 Sarcoma 1 Plasma cell 1 Genitourinary 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Interventions

Doxorubicin 44 Imatinib Mesylate 33 pembrolizumab 23 Sunitinib 22 Gemcitabine 22 Cyclophosphamide 22 Temozolomide 17 Irinotecan 14 Bevacizumab 14 Docetaxel 13 nilotinib 12 Trabectedin 12 ripretinib 11 pazopanib 11 olaratumab 10 eribulin 10 regorafenib 9 fludarabine 9 avapritinib 9 Fluorouracil 9 Carboplatin 9 Paclitaxel 8 Nivolumab 8 Ifosfamide 8 Ibandronic Acid 8 spartalizumab 7 anlotinib 7 Vincristine 7 Radiation 7 Ipilimumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Methotrexate × Sarcoma × Clear all

NCT02383901 2016-09-05

FORTO

Isofol Medical AB

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡